Caribou Biosciences Stock

cariboubio.com | BioTech | Founded: 2011 | Funding to Date: $41,550,000

Caribou Biosciences is a leading clinical-stage CRISPR genome editing biotechnology company developing an internal pipeline of off-the-shelf, genome-edited CAR-T and natural killer (NK) cell therapies.

TEAM

Management Team
  • Rachel Haurwitz Ph.D - Co-Founder, Board Member, President and Chief Executive Officer
  • Barbara McClung - Chief Legal Officer and Corporate Secretary
  • Steven Kanner Ph.D - Chief Scientific Officer
  • Edny Inui - Director, Business Development
  • Timothy Herpin Ph.D - Chief Business Officer
  • Martin Jinek Ph.D - Co-Founder & Scientific Advisor
  • James Berger - Co-Founder
  • Chris Fuller - Vice President, Informatics
  • Scott Gradia Ph.D - Vice President of Platform Research
  • Jennifer Doudna Ph.D - Co-Founder & Scientific Advisor
Board Members
  • Natalie Sacks MD -
  • Philip Austin - Anterra Capital
  • Rachel Haurwitz Ph.D -
  • Robert Weisskoff Ph.D -

Other companies like Caribou Biosciences in the BioTech sector

Ginkgo Bioworks
BioTech
Est. Val.: $4.89B
Human Longevity
BioTech
Est. Val.: $50,396,793
Life Biosciences
BioTech
Est. Val.: $500,000,000
American Gene Technologies International
BioTech
Est. Val.: $265,000,000
Mammoth Biosciences
BioTech
Est. Val.: $145,000,000

NEWS

X